News
Essa Pharma Announces Closing of $130 Million Public Offering of Common Stock
ESSA Pharma Announces Pricing of Public Offering of Common Shares
ESSA Pharma Announces Proposed Public Offering of Common Shares
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020
ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference
ESSA Pharma to Participate in Upcoming Investor Conferences
ESSA Pharma Inc. Announce the Delisting from the TSX-V